Identification of defactinib derivatives targeting focal adhesion kinase using ensemble docking, molecular dynamics simulations and binding free energy calculations

References

• Aguayo-Ortiz, R., Guzman-Ocampo, D. C., & Dominguez, L. (2022). Insights into the binding of morin to human gamma D-crystallin. Biophysical Chemistry, 282, 106750. https://doi.org/10.1016/j.bpc.2021.106750
   PubMed Web of Science ®Google Scholar
• Ahrari, S., Mogharrab, N., & Navapour, L. (2017). Interconversion of inactive to active conformation of Mark2: Insights from molecular modeling and molecular dynamics simulation. Archives of Biochemistry and Biophysics, 630, 66–80. https://doi.org/10.1016/j.abb.2017.07.002
   PubMed Web of Science ®Google Scholar
• Ahrari, S., Mogharrab, N., & Navapour, L. (2020). Structure and dynamics of inactive and active Mark4: Conformational switching through the activation process. Journal of Biomolecular Structure & Dynamics, 38(8), 2468–2481. https://doi.org/10.1080/07391102.2019.1655479
   PubMed Web of Science ®Google Scholar
• Amaro, R. E., Baudry, J., Chodera, J., Demir, O., McCammon, J. A., Miao, Y. L., & Smith, J. C. (2018). Ensemble docking in drug discovery. Biophysical Journal, 114(10), 2271–2278. https://doi.org/10.1016/j.bpj.2018.02.038
   PubMed Web of Science ®Google Scholar
• Aqvist, J., Medina, C., & Samuelsson, J. E. (1994). A new method for predicting binding affinity in computer-aided drug design. Protein Engineering, 7(3), 385–391. https://doi.org/10.1093/protein/7.3.385
   PubMedGoogle Scholar
• Arold, S. T., Hoellerer, M. K., & Noble, M. E. M. (2002). The structural basis of localization and signaling by the focal adhesion targeting domain. Structure (London, England : 1993), 10(3), 319–327. https://doi.org/10.1016/S0969-2126(02)00717-7
   PubMed Web of Science ®Google Scholar
• Auger, K., Smitheman, K. N., Korenchuk, S., McHugh, C., Kruger, R., Van Aller, G., Smallwood, A., Gontarek, R. R., Faitg, T., & Johnson, N. (2012). The focal adhesion kinase inhibitor Gsk2256098: A potent and selective inhibitor for the treatment of cancer. European Journal of Cancer, 48, 118. https://doi.org/10.1016/S0959-8049(12)72185-8
   Web of Science ®Google Scholar
• Bateman, A., Martin, M. J., O'Donovan, C., Magrane, M., Alpi, E., Antunes, R., Bely, B., Bingley, M., Bonilla, C., & Britto, R. (2017). Uniprot: The universal protein knowledgebase. Nucleic Acids Research. 45(D1), D158–D169. https://doi.org/10.1093/nar/gkw1099
   PubMed Web of Science ®Google Scholar
• Bateman, A., Martin, M. J., O'Donovan, C., Magrane, M., Apweiler, R., Alpi, E., Antunes, R., Ar-Ganiska, J., Bely, B., & Bingley, M. (2015). Uniprot: A hub for protein information. Nucleic Acids Research. 43(D1), D204–D212. https://doi.org/10.1093/nar/gku989
   PubMed Web of Science ®Google Scholar
• Bateman, A., Martin, M. J., Orchard, S., Magrane, M., Alpi, E., Bely, B., Bingley, M., Britto, R., Bursteinas, B., & Busiello, G. (2019). Uniprot: A worldwide hub of protein knowledge. Nucleic Acids Research. 47(D1), D506–D515. https://doi.org/10.1093/nar/gky1049
   PubMed Web of Science ®Google Scholar
• Bayly, C. I., Cieplak, P., Cornell, W. D., & Kollman, P. A. (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. The Journal of Physical Chemistry, 97(40), 10269–10280. https://doi.org/10.1021/j100142a004
   Web of Science ®Google Scholar
• Bera, I., & Payghan, P. V. (2019). Use of molecular dynamics simulations in structure-based drug discovery. Current Pharmaceutical Design, 25(31), 3339–3349. https://doi.org/10.2174/1381612825666190903153043
   PubMed Web of Science ®Google Scholar
• Berger, B.-T., Amaral, M., Kokh, D. B., Nunes-Alves, A., Musil, D., Heinrich, T., Schröder, M., Neil, R., Wang, J., Navratilova, I., Bomke, J., Elkins, J. M., Müller, S., Frech, M., Wade, R. C., & Knapp, S. (2021). Structure-kinetic relationship reveals the mechanism of selectivity of Fak inhibitors over Pyk2. Cell Chemical Biology, 28(5), 686–698.e7. https://doi.org/10.1016/j.chembiol.2021.01.003
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Bhagat, R. T., Butle, S. R., Khobragade, D. S., Wankhede, S. B., Prasad, C. C., Mahure, D. S., & Armarkar, A. V. (2021). Molecular docking in drug discovery. Journal of Pharmaceutical Research International, 33(30B), 46–58. https://doi.org/10.9734/jpri/2021/v33i30B31639
   Web of Science ®Google Scholar
• Brami-Cherrier, K., Gervasi, N., Arsenieva, D., Walkiewicz, K., Boutterin, M.-C., Ortega, A., Leonard, P. G., Seantier, B., Gasmi, L., Bouceba, T., Kadaré, G., Girault, J.-A., & Arold, S. T. (2014). Fak dimerization controls its kinase-dependent functions at focal adhesions. The EMBO Journal, 33(4), 356–370. https://doi.org/10.1002/embj.201386399
   PubMed Web of Science ®Google Scholar
• Bren, U., Martinek, V., & Florian, J. (2006). Free energy simulations of uncatalyzed DNA replication fidelity: Structure and stability of T center Dot G and Dttp center Dot G terminal DNA mismatches flanked by a single dangling nucleotide. The Journal of Physical Chemistry. B, 110(21), 10557–10566. https://doi.org/10.1021/jp060292b
   PubMed Web of Science ®Google Scholar
• Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Christie, C. H., Dalenberg, K., Di Costanzo, L., Duarte, J. M., Dutta, S., Feng, Z., Ganesan, S., Goodsell, D. S., Ghosh, S., Green, R. K., Guranović, V., Guzenko, D., Hudson, B. P., … Zhuravleva, M. (2021). RCSB protein data bank: powerful new tools for exploring 3d structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Research, 49(D1), D437–D451. https://doi.org/10.1093/nar/gkaa1038
   PubMed Web of Science ®Google Scholar
• Case, D. A., Ben-Shalom, K. B., Brozell, I. Y., Cerutti, S. R., Cheatham, D. S., III, T. E., Cruzeiro, V. W. D., Darden, T. A., Duke, R. E., Giambasu, G., Gilson, M. K., Gohlke, H., Goetz, A. W., Harris, R., Izadi, S., Izmailov, S. A., Kasavajhala, K., Kovalenko, A., Krasny, R., … Kollman, P. A. (2020). Amber 2020. University of California.
   Google Scholar
• Chauhan, A., & Khan, T. (2021). Focal adhesion kinase-an emerging viable target in cancer and development of focal adhesion kinase inhibitors. Chemical Biology & Drug Design, 97(3), 774–794. https://doi.org/10.1111/cbdd.13808
   PubMed Web of Science ®Google Scholar
• Chen, G. L., Seukep, A. J., & Guo, M. Q. (2020). Recent advances in molecular docking for the research and discovery of potential marine drugs. Marine Drugs, 18(11), 545. https://doi.org/10.3390/md18110545
   PubMed Web of Science ®Google Scholar
• Chen, T., Liu, Y., Liu, J., Tang, M., Huang, H., Bai, C., Si, W., Yang, T., Yuan, X., Wen, Y., & Chen, L. (2022). Design, synthesis and biological evaluation of novel Fak inhibitors with better selectivity over Ir than Tae226. Bioorganic Chemistry, 124, 105790. https://doi.org/10.1016/j.bioorg.2022.105790
   PubMed Web of Science ®Google Scholar
• Chen, T., Liu, Y., Shi, M. S., Tang, M. H., Si, W. T., Yuan, X., Wen, Y., & Chen, L. J. (2021). Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase. Bioorganic and Medicinal Chemistry Letters. 54(9), 128433. https://doi.org/10.1016/j.bmcl.2021.128433
   PubMedGoogle Scholar
• Chen, Y., Yuan, X., Tang, M., Shi, M., Yang, T., Liu, K., Deng, D., & Chen, L. (2022). Degrading Flt3-Itd protein by proteolysis targeting chimera (Protac). Bioorganic Chemistry, 119, 105508. https://doi.org/10.1016/j.bioorg.2021.105508
   PubMed Web of Science ®Google Scholar
• Cheng, P., Li, J. J., Wang, J., Zhang, X. Y., & Zhai, H. L. (2018). Investigations of Fak inhibitors: A combination of 3d-Qsar, docking, and molecular dynamics simulations studies. Journal of Biomolecular Structure & Dynamics, 36(6), 1529–1549. https://doi.org/10.1080/07391102.2017.1329095
   PubMed Web of Science ®Google Scholar
• Cho, H., Shin, I., Yoon, H., Jeon, E., Lee, J., Kim, Y., Ryu, S., Song, C., Kwon, N. H., Moon, Y., Kim, S., Kim, N. D., Choi, H. G., & Sim, T. (2021). Identification of thieno 3,2-D pyrimidine derivatives as dual inhibitors of focal adhesion kinase and FMS-like tyrosine kinase 3. Journal of Medicinal Chemistry, 64(16), 11934–11957. https://doi.org/10.1021/acs.jmedchem.1c00459
   PubMed Web of Science ®Google Scholar
• Choi, H.-S., Wang, Z., Richmond, W., He, X., Yang, K., Jiang, T., Karanewsky, D., Gu, X-j., Zhou, V., Liu, Y., Che, J., Lee, C. C., Caldwell, J., Kanazawa, T., Umemura, I., Matsuura, N., Ohmori, O., Honda, T., Gray, N., & He, Y. (2006). Design and synthesis of 7h-pyrrolo 2,3-D pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorganic & Medicinal Chemistry Letters, 16(10), 2689–2692. https://doi.org/10.1016/j.bmcl.2006.02.032
   PubMed Web of Science ®Google Scholar
• Choi, H.-S., Wang, Z., Richmond, W., He, X., Yang, K., Jiang, T., Sim, T., Karanewsky, D., Gu, X-j., Zhou, V., Liu, Y., Ohmori, O., Caldwell, J., Gray, N., & He, Y. (2006). Design and synthesis of 7h-pyrrolo 2,3-D pyrimidines as focal adhesion kinase inhibitors. Part 1. Bioorganic & Medicinal Chemistry Letters, 16(8), 2173–2176. https://doi.org/10.1016/j.bmcl.2006.01.053
   PubMed Web of Science ®Google Scholar
• Chuang, H. H., Zhen, Y. Y., Tsai, Y. C., Chuang, C. H., Hsiao, M. C., Huang, M. S., & Yang, C. J. (2022). Fak in cancer: From mechanisms to therapeutic strategies. International Journal of Molecular Sciences, 23(3), 1726. https://doi.org/10.3390/ijms23031726
   PubMed Web of Science ®Google Scholar
• Cooper, J., & Giancotti, F. G. (2019). Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell, 35(3), 347–367. https://doi.org/10.1016/j.ccell.2019.01.007
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007). Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallographica. Section D, Biological Crystallography, 63(Pt 1), 80–93. https://doi.org/10.1107/s0907444906047287
   PubMedGoogle Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle Mesh Ewald: An N⋅Log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021). Targeting Fak in anticancer combination therapies. Nature Reviews Cancer, 21(5), 313–324. https://doi.org/10.1038/s41568-021-00340-6
   PubMed Web of Science ®Google Scholar
• Del Mistro, G., Riemann, S., Schindler, S., Beissert, S., Kontermann, R. E., Ginolhac, A., Halder, R., Presta, L., Sinkkonen, L., Sauter, T., & Kulms, D. (2022). Focal adhesion kinase plays a dual role in trail resistance and metastatic outgrowth of malignant melanoma. Cell Death & Disease, 13(1), 15. https://doi.org/10.1038/s41419-022-04502-8
   Web of Science ®Google Scholar
• Dhani, N. C., Burris, H. A., Siu, L. L., Camidge, D. R., Mileshkin, L. R., Xu, H., Pierce, K. J., Fahey, N. R., Fingert, H. J., & Shreeve, S. M. (2010). Final report of phase i clinical, pharmacokinetic (Pk), pharmacodynamic (Pd) study of Pf-00562271 targeting focal adhesion kinase (Fak) in patients (Pts) with solid tumors. Journal of Clinical Oncology, 28(15_suppl), 3028–3028. https://doi.org/10.1200/jco.2010.28.15_suppl.3028
   PubMed Web of Science ®Google Scholar
• Du, Q. Q., Qian, Y., Yao, X. J., & Xue, W. W. (2020). Elucidating the tight-binding mechanism of two oral anticoagulants to factor Xa by using induced-fit docking and molecular dynamics simulation. Journal of Biomolecular Structure & Dynamics, 38(2), 625–633. https://doi.org/10.1080/07391102.2019.1583605
   PubMed Web of Science ®Google Scholar
• Feller, S. E., Zhang, Y. H., Pastor, R. W., & Brooks, B. R. (1995). Constant pressure molecular dynamics simulation: The Langevin Piston method. Journal of Chemical Physics. 103(11), 4613–4621. https://doi.org/10.1063/1.470648
   Web of Science ®Google Scholar
• Fontana, R., & Vivo, M. (2018). Dynamics of P14arf and focal adhesion kinase-mediated autophagy in cancer. Cancers, 10(7), 221. https://doi.org/10.3390/cancers10070221
   PubMed Web of Science ®Google Scholar
• Fuhrmann, J., Rurainski, A., Lenhof, H. P., & Neumann, D. (2010). A new Lamarckian genetic algorithm for flexible ligand-receptor docking. Journal of Computational Chemistry, 31(9), 1911–1918. https://doi.org/10.1002/jcc.21478
   PubMed Web of Science ®Google Scholar
• Garron, M. L., Arthos, J., Guichou, J. F., McNally, J., Cicala, C., & Arold, S. T. (2008). Structural basis for the interaction between focal adhesion kinase and Cd4. Journal of Molecular Biology, 375(5), 1320–1328. https://doi.org/10.1016/j.jmb.2007.11.040
   PubMed Web of Science ®Google Scholar
• Gasteiger, J., & Marsili, M. (1980). Iterative partial equalization of orbital electronegativity—A rapid access to atomic charges. Tetrahedron, 36(22), 3219–3228. https://doi.org/10.1016/0040-4020(80)80168-2
   Web of Science ®Google Scholar
• Gaussian 09. (2009). Gaussian, Inc. Wallingford CT, 2016.
   Google Scholar
• George, D. M., Breinlinger, E. C., Friedman, M., Zhang, Y., Wang, J., Argiriadi, M., Bansal-Pakala, P., Barth, M., Duignan, D. B., Honore, P., Lang, Q., Mittelstadt, S., Potin, D., Rundell, L., & Edmunds, J. J. (2015). Discovery of selective and orally bioavailable protein kinase c theta (Pkc Theta) inhibitors from a fragment hit. Journal of Medicinal Chemistry, 58(1), 222–236. https://doi.org/10.1021/jm500669m
   PubMed Web of Science ®Google Scholar
• Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., Li, M., Weaver, D. T., Vaikus, L., Keegan, M., Horobin, J. C., & Burns, T. F. (2020). Phase 2 study of the focal adhesion kinase inhibitor defactinib (Vs-6063) in previously treated advanced Kras mutant non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 139, 60–67. https://doi.org/10.1016/j.lungcan.2019.10.033
   PubMed Web of Science ®Google Scholar
• Gerber, D. E., Ramalingam, S. S., Morgensztern, D., Kelly, R. J., Burns, T. F., Lopez-Chavez, A., Spigel, D. R., Wehbe, A. M., Sorensen, R., Weaver, D. T., Horobin, J., Keegan, M., Scaglioni, P. P., Camidge, D. R, & VS-6063 PIs (2014). A phase 2 study of defactinib (Vs-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (Fak), in patients with Kras-Mutant non-small cell lung cancer. Journal of Clinical Oncology, 32(15_suppl), TPS8126–TPS8126. https://doi.org/10.1200/jco.2014.32.15_suppl.tps8126
   Web of Science ®Google Scholar
• Gilson, M. K., & Zhou, H. X. (2007). Calculation of protein-ligand binding affinities. Annual Review of Biophysics and Biomolecular Structure, 36, 21–42. https://doi.org/10.1146/annurev.biophys.36.040306.132550
   PubMedGoogle Scholar
• Gradler, U., Bomke, J., Musil, D., Dresing, V., Lehmann, M., Holzemann, G., Greiner, H., Esdar, C., Krier, M., & Heinrich, T. (2013). Fragment-based discovery of focal adhesion kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 23(19), 5401–5409. https://doi.org/10.1016/j.bmcl.2013.07.050
   PubMed Web of Science ®Google Scholar
• Haile, P. A., Casillas, L. N., Votta, B. J., Wang, G. Z., Charnley, A. K., Dong, X., Bury, M. J., Romano, J. J., Mehlmann, J. F., King, B. W., Erhard, K. F., Hanning, C. R., Lipshutz, D. B., Desai, B. M., Capriotti, C. A., Schaeffer, M. C., Berger, S. B., Mahajan, M. K., Reilly, M. A., … Marquis, R. W. (2019). Discovery of a first-in-class receptor interacting protein 2 (Rip2) kinase specific clinical candidate, 2-((4-(benzo d thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl) oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases. Journal of Medicinal Chemistry, 62(14), 6482–6494. https://doi.org/10.1021/acs.jmedchem.9b00575
   PubMed Web of Science ®Google Scholar
• Heinrich, T., Seenisamy, J., Emmanuvel, L., Kulkarni, S. S., Bomke, J., Rohdich, F., Greiner, H., Esdar, C., Krier, M., Grädler, U., & Musil, D. (2013). Fragment-based discovery of new highly substituted 1h-pyrrolo 2,3-b - and 3h-imidazolo 4,5-b -pyridines as focal adhesion kinase inhibitors. Journal of Medicinal Chemistry, 56(3), 1160–1170. https://doi.org/10.1021/jm3016014
   PubMed Web of Science ®Google Scholar
• Hirt, U. A., Waizenegger, I. C., Schweifer, N., Haslinger, C., Gerlach, D., Braunger, J., Weyer-Czernilofsky, U., Stadtmüller, H., Sapountzis, I., Bader, G., Zoephel, A., Bister, B., Baum, A., Quant, J., Kraut, N., Garin-Chesa, P., & Adolf, G. R. (2018). Efficacy of the highly selective focal adhesion kinase inhibitor Bi 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis, 7(2), 11. https://doi.org/10.1038/s41389-018-0032-z
   PubMedGoogle Scholar
• Hoellerer, M. K., Noble, M., E. M., Labesse, G., Campbell, I. D., Werner, J. M., & Arold, S. T. (2003). Molecular recognition of Paxillin Ld motifs by the focal adhesion targeting domain. Structure, 11(10), 1207–1217. https://doi.org/10.1016/j.str.2003.08.010
   PubMed Web of Science ®Google Scholar
• Ignjatovic, V. B., Miljus, J. R. J., Roncevic, J. V., Tatic, S. B., Dencic, T. M. I., Doric, I. D., & Selemetjev, S. A. (2022). Focal adhesion kinase splicing and protein activation in papillary thyroid carcinoma progression. Histochemistry and Cell Biology, 157(2), 183–194. https://doi.org/10.1007/s00418-021-02056-y
   PubMed Web of Science ®Google Scholar
• Infante, J. R., Camidge, D. R., Mileshkin, L. R., Chen, E. X., Hicks, R. J., Rischin, D., Fingert, H., Pierce, K. J., Xu, H., Roberts, W. G., Shreeve, S. M., Burris, H. A., & Siu, L. L. (2012). Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of Pf-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(13), 1527–1533. https://doi.org/10.1200/jco.2011.38.9346
   PubMed Web of Science ®Google Scholar
• Iwatani, M., Iwata, H., Okabe, A., Skene, R. J., Tomita, N., Hayashi, Y., Aramaki, Y., Hosfield, D. J., Hori, A., Baba, A., & Miki, H. (2013). Discovery and characterization of novel allosteric Fak inhibitors. European Journal of Medicinal Chemistry, 61, 49–60. https://doi.org/10.1016/j.ejmech.2012.06.035
   PubMed Web of Science ®Google Scholar
• Jakhar, R., Dangi, M., Khichi, A., & Chhillar, A. K. (2020). Relevance of molecular docking studies in drug designing. Current Bioinformatics, 15(4), 270–278. https://doi.org/10.2174/1574893615666191219094216
   Web of Science ®Google Scholar
• Jones, S. F., Shapiro, G., Bendell, J. C., Chen, E. X., Bedard, P., Cleary, J. M., Pandya, S., Pierce, K. J., Houk, B., Hosea, N., Zandi, K. S., Roberts, W. G., Shreeve, S. M., & Siu, L. L. (2011). Phase I study of Pf-04554878, a second-generation focal adhesion kinase (Fak) inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology, 29(15_suppl), 3002–3002. https://doi.org/10.1200/jco.2011.29.15_suppl.3002
   Web of Science ®Google Scholar
• Jones, S. F., Siu, L. L., Bendell, J. C., Cleary, J. M., Razak, A. R. A., Infante, J. R., Pandya, S. S., Bedard, P. L., Pierce, K. J., Houk, B., Roberts, W. G., Shreeve, S. M., & Shapiro, G. I. (2015). A phase i study of Vs-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 33(5), 1100–1107. https://doi.org/10.1007/s10637-015-0282-y
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79(2), 926–935. https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Kadare, G., Gervasi, N., Brami-Cherrier, K., Blockus, H., El Messari, S., Arold, S. T., & Girault, J. A. (2015). Conformational dynamics of the focal adhesion targeting domain control specific functions of focal adhesion kinase in cells. The Journal of Biological Chemistry, 290(1), 478–491. https://doi.org/10.1074/jbc.M114.593632
   PubMed Web of Science ®Google Scholar
• King, E., Aitchison, E., Li, H., & Luo, R. (2021). Recent developments in free energy calculations for drug discovery. Frontiers in Molecular Biosciences, 8, 24. https://doi.org/10.3389/fmolb.2021.712085
   Web of Science ®Google Scholar
• Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., Zecha, J., Reiter, K., Qiao, H., Helm, D., Koch, H., Schoof, M., Canevari, G., Casale, E., Depaolini, S. R., … Kuster, B. (2017). The target landscape of clinical kinase drugs. Science, 358(6367), 16. https://doi.org/10.1126/science.aan4368
   Web of Science ®Google Scholar
• Koolman, H., Heinrich, T., & Musil, D. Focal adhesion kinase catalytic domain in complex with pyrrolo[2,3-D]thiazole. https://doi.org/10.2210/pdb3PXK/pdb
   Google Scholar
• Kurmasheva, R. T., Gorlick, R., Kolb, E. A., Keir, S. T., Maris, J. M., Lock, R. B., Carol, H., Kang, M., Reynolds, C. P., & Wu, J. R. (2017). Initial testing of Vs-4718, a novel inhibitor of focal adhesion kinase (Fak), against pediatric tumor models by the pediatric preclinical testing program. Pediatric Blood & Cancer, 64(4), 5. https://doi.org/10.1002/pbc.26304
   Web of Science ®Google Scholar
• Law, R. P., Nunes, J., Chung, C.-W., Bantscheff, M., Buda, K., Dai, H., Evans, J. P., Flinders, A., Klimaszewska, D., Lewis, A. J., Muelbaier, M., Scott-Stevens, P., Stacey, P., Tame, C. J., Watt, G. F., Zinn, N., Queisser, M. A., Harling, J. D., & Benowitz, A. B. (2021). Discovery and characterisation of highly cooperative FAK-degrading protacs. Angewandte Chemie (International ed. in English), 60(43), 23327–23334. https://doi.org/10.1002/anie.202109237
   PubMed Web of Science ®Google Scholar
• Le Large, T. Y. S., Bijlsma, M. F., El Hassouni, B., Mantini, G., Lagerweij, T., Henneman, A. A., Funel, N., Kok, B., Pham, T. V., & de Haas, R. (2021). Focal adhesion kinase inhibition synergizes with Nab-paclitaxel to target pancreatic ductal adenocarcinoma. Journal of Experimental & Clinical Cancer Research, 40(1), 12. https://doi.org/10.1186/s13046-021-01892-z
   PubMed Web of Science ®Google Scholar
• Lee, C. C. (2006). Crystal structure of focal adhesion kinase domain complexed with 7h-pyrrolo [2,3-D] pyrimidine derivative. https://doi.org/10.2210/pdb2ETM/pdb
   Google Scholar
• Lee, C. C. (2007). Crystal structure of focal adhesion kinase domain with 2 molecules in the asymmetric unit complexed with Adp and Atp. https://doi.org/10.2210/pdb2IJM/pdb
   Google Scholar
• Lee, F. S., Chu, Z. T., Bolger, M. B., & Warshel, A. (1992). Calculations of antibody-antigen interactions: Microscopic and semi-microscopic evaluation of the free energies of binding of phosphorylcholine analogs to Mcpc603. Protein Engineering, 5(3), 215–228. https://doi.org/10.1093/protein/5.3.215
   PubMedGoogle Scholar
• Lee, M. S., Salsbury, F. R., & Olson, M. A. (2004). An efficient hybrid explicit/implicit solvent method for biomolecular simulations. Journal of Computational Chemistry, 25(16), 1967–1978. https://doi.org/10.1002/jcc.20119
   PubMed Web of Science ®Google Scholar
• Li, H., Gao, Y. Z., & Ren, C. C. (2021). Focal adhesion kinase inhibitor Bi 853520 inhibits cell proliferation, migration and EMT process through Pi3k/Akt/Mtor signaling pathway in ovarian cancer. Discover Oncology, 12(1), 14. https://doi.org/10.1007/s12672-021-00425-6
   PubMedGoogle Scholar
• Lietha, D., & Eck, M. J. (2008). Crystal structures of the Fak kinase in complex with Tae226 and related bis-anilino pyrimidine inhibitors reveal a helical Dfg conformation. PLoS One, 3(11), e3800. https://doi.org/10.1371/journal.pone.0003800
   PubMed Web of Science ®Google Scholar
• Lim, S. T., Mikolon, D., Stupack, D. G., & Schlaepfer, D. D. (2008). Ferm control of Fak function—Implications for cancer therapy. Cell Cycle (Georgetown, Tex.), 7(15), 2306–2314. https://doi.org/10.4161/cc.6367
   PubMed Web of Science ®Google Scholar
• Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., … Borzilleri, R. M. (2004). Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-m ethylpyrimidin-4-ylamino)thiazole-5-carboxamide (Bms-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry, 47(27), 6658–6661. https://doi.org/10.1021/jm049486a
   PubMed Web of Science ®Google Scholar
• Lu, Y., & Sun, H. Y. (2020). Progress in the development of small molecular inhibitors of focal adhesion kinase (Fak). Journal of Medicinal Chemistry, 63(23), 14382–14403. https://doi.org/10.1021/acs.jmedchem.0c01248
   PubMed Web of Science ®Google Scholar
• Lv, P. C., Chen, K., & Zhu, H. L. (2021). Recent advances of small molecule focal adhesion kinase (Fak) inhibitors as promising anticancer therapeutics. Current Medicinal Chemistry, 28(34), 6977–6989. https://doi.org/10.2174/0929867328666210331143827
   PubMed Web of Science ®Google Scholar
• Margiotta, E., van der Lubbe, S. C. C., Santos, L. D., Paragi, G., Moro, S., Bickelhaupt, F. M., & Guerra, C. F. (2020). Halogen bonds in ligand-protein systems: Molecular orbital theory for drug design. Journal of Chemical Information and Modeling, 60(3), 1317–1328. https://doi.org/10.1021/acs.jcim.9b00946
   PubMed Web of Science ®Google Scholar
• Martyna, G. J., Tobias, D. J., & Klein, M. L. (1994). Constant pressure molecular dynamics algorithms. Journal of Chemical Physics. 101(5), 4177–4189. https://doi.org/10.1063/1.467468
   Web of Science ®Google Scholar
• Matsukura, L., & Miyashita, N. (2020). Binding mechanism of anti-cancer target Hsp90 and peptide drug. Biophysical Journal, 118(3), 512A–512A. https://doi.org/10.1016/j.bpj.2019.11.2820
   Web of Science ®Google Scholar
• Modi, V., & Dunbrack, R. L. (2019). Defining a new nomenclature for the structures of active and inactive kinases. Proceedings of the National Academy of Sciences of the United States of America, 116(14), 6818–6827. https://doi.org/10.1073/pnas.1814279116
   PubMed Web of Science ®Google Scholar
• Momin, A. A., Hameed, U. F. S., & Arold, S. T. (2019). Passenger sequences can promote interlaced dimers in a common variant of the maltose-binding protein. Scientific Reports, 9(1), 9. https://doi.org/10.1038/s41598-019-56718-y
   PubMedGoogle Scholar
• Morris, C. J., & Della Corte, D. (2021). Using molecular docking and molecular dynamics to investigate protein-ligand interactions. Modern Physics Letters B, 35(08), 2130002. https://doi.org/10.1142/S0217984921300027
   Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). Autodock4 and Autodocktools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Mousson, A., Legrand, M., Steffan, T., Vauchelles, R., Carl, P., Gies, J.-P., Lehmann, M., Zuber, G., De Mey, J., Dujardin, D., Sick, E., & Rondé, P. (2021). Inhibiting Fak-Paxillin interaction reduces migration and invadopodia-mediated matrix degradation in metastatic melanoma cells. Cancers, 13(8), 1871. https://doi.org/10.3390/cancers13081871
   PubMed Web of Science ®Google Scholar
• Mousson, A., Sick, E., Carl, P., Dujardin, D., De Mey, J., & Ronde, P. (2018). Targeting focal adhesion kinase using inhibitors of protein-protein interactions. Cancers, 10(9), 278. https://doi.org/10.3390/cancers10090278
   PubMed Web of Science ®Google Scholar
• Mustafa, M., Abd El-Hafeez, A. A., Abdelhafeez, D. A., Abdelhamid, D., Mostafa, Y. A., Ghosh, P., Hayallah, A. M., & Abuo-Rahma, G. E. A. (2021). Fak inhibitors as promising anticancer targets: Present and future directions. Future Medicinal Chemistry, 13(18), 1559–1590. https://doi.org/10.4155/fmc-2021-0015
   PubMed Web of Science ®Google Scholar
• Naïm, M., Bhat, S., Rankin, K. N., Dennis, S., Chowdhury, S. F., Siddiqi, I., Drabik, P., Sulea, T., Bayly, C. I., Jakalian, A., & Purisima, E. O. (2007). Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. Journal of Chemical Information and Modeling, 47(1), 122–133. https://doi.org/10.1021/ci600406v
   PubMed Web of Science ®Google Scholar
• Nana, F. A., Vanderputten, M., & Ocak, S. (2019). Role of focal adhesion kinase in small-cell lung cancer and its potential as a therapeutic target. Cancers, 11(11), 1683. https://doi.org/10.3390/cancers11111683
   PubMed Web of Science ®Google Scholar
• Nowakowski, J., Cronin, C. N., McRee, D. E., Knuth, M. W., Nelson, C. G., Pavletich, N. P., Rogers, J., Sang, B.-C., Scheibe, D. N., Swanson, R. V., & Thompson, D. A. (2002). Structures of the cancer-related aurora-a, Fak, and Epha2 protein kinases from nanovolume crystallography. Structure (London, England : 1993), 10(12), 1659–1667. https://doi.org/10.1016/S0969-2126(02)00907-3
   PubMed Web of Science ®Google Scholar
• O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33. https://doi.org/10.1186/1758-2946-3-33
   Web of Science ®Google Scholar
• Osipov, A., B. Blair, A., Liberto, J., Wang, J., Li, K., Herbst, B., Xu, Y., Li, S., Niu, N., Rashid, R., Ding, D., Liu, Y., Wang, Z., L. Wolfgang, C., A. Burkhart, R., Laheru, D., & Zheng, L. (2021). Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through Cd8 + T cells. Cancer Biology and Medicine, 18(1), 206–214. https://doi.org/10.20892/j.issn.2095-3941.2020.0273
   PubMed Web of Science ®Google Scholar
• Ott, G. R., Cheng, M., Learn, K. S., Wagner, J., Gingrich, D. E., Lisko, J. G., Curry, M., Mesaros, E. F., Ghose, A. K., Quail, M. R., Wan, W., Lu, L., Dobrzanski, P., Albom, M. S., Angeles, T. S., Wells-Knecht, K., Huang, Z., Aimone, L. D., Bruckheimer, E., … Dorsey, B. D. (2016). Discovery of clinical candidate Cep-37440, a selective inhibitor of focal adhesion kinase (Fak) and anaplastic lymphoma kinase (Alk). Journal of Medicinal Chemistry, 59(16), 7478–7496. https://doi.org/10.1021/acs.jmedchem.6b00487
   PubMed Web of Science ®Google Scholar
• Panera, N., Crudele, A., Romito, I., Gnani, D., & Alisi, A. (2017). Focal adhesion kinase: Insight into molecular roles and functions in hepatocellular carcinoma. International Journal of Molecular Sciences, 18(1), 99. https://doi.org/10.3390/ijms18010099
   PubMed Web of Science ®Google Scholar
• Pang, X.-J., Liu, X.-J., Liu, Y., Liu, W.-B., Li, Y.-R., Yu, G.-X., Tian, X.-Y., Zhang, Y.-B., Song, J., Jin, C.-Y., & Zhang, S.-Y. (2021). Drug discovery targeting focal adhesion kinase (Fak) as a promising cancer therapy. Molecules, 26(14), 4250. https://doi.org/10.3390/molecules26144250
   PubMed Web of Science ®Google Scholar
• Perdih, A., Bren, U., & Solmajer, T. (2009). Binding free energy calculations of N-sulphonyl-glutamic acid inhibitors of murd ligase. Journal of Molecular Modeling, 15(8), 983–996. https://doi.org/10.1007/s00894-009-0455-8
   PubMed Web of Science ®Google Scholar
• Popow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., Koegl, M., McConnell, D. B., Pearson, M., Rieger, M., Rinnenthal, J., Roessler, V., Schrenk, A., Spina, M., Steurer, S., … Ettmayer, P. (2019). Highly selective Ptk2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions. Journal of Medicinal Chemistry, 62(5), 2508–2520. https://doi.org/10.1021/acs.jmedchem.8b01826
   PubMed Web of Science ®Google Scholar
• Qi, Y. H., Li, Y., Fang, Y., Gao, H., Qiang, B. C., Wang, S. X., & Zhang, H. B. (2021). Design, synthesis, biological evaluation, and molecular docking of 2,4-diaminopyrimidine derivatives targeting focal adhesion kinase as tumor radiotracers. Molecular Pharmaceutics, 18(4), 1634–1642. https://doi.org/10.1021/acs.molpharmaceut.0c01088
   PubMed Web of Science ®Google Scholar
• Quispe, P. A., Lavecchia, M. J., & Leon, I. E. (2022). Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence. Drug Discovery Today, 27(2), 664–674. https://doi.org/10.1016/j.drudis.2021.11.025
   PubMed Web of Science ®Google Scholar
• Rashid, M., Belmont, J., Carpenter, D., Turner, C. E., & Olson, E. C. (2017). Neural-specific deletion of the focal adhesion adaptor protein paxillin slows migration speed and delays cortical layer formation. Development (Cambridge, England), 144(21), 4002–4014. https://doi.org/10.1242/dev.147934
   PubMed Web of Science ®Google Scholar
• Riel, A. M. S., Rowe, R. K., Ho, E. N., Carlsson, A.-C C., Rappé, A. K., Berryman, O. B., & Ho, P. S. (2019). Hydrogen bond enhanced halogen bonds: A synergistic interaction in chemistry and biochemistry. Accounts of Chemical Research, 52(10), 2870–2880. https://doi.org/10.1021/acs.accounts.9b00189
   PubMed Web of Science ®Google Scholar
• Rigiracciolo, D. C., Cirillo, F., Talia, M., Muglia, L., Gutkind, J. S., Maggiolini, M., & Lappano, R. (2021). Focal adhesion kinase fine tunes multifaced signals toward breast cancer progression. Cancers, 13(4), 645. https://doi.org/10.3390/cancers13040645
   PubMed Web of Science ®Google Scholar
• Roberts, W. G., Ung, E., Whalen, P., Cooper, B., Hulford, C., Autry, C., Richter, D., Emerson, E., Lin, J., Kath, J., Coleman, K., Yao, L., Martinez-Alsina, L., Lorenzen, M., Berliner, M., Luzzio, M., Patel, N., Schmitt, E., LaGreca, S., … Vajdos, F. (2008). Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, Pf-562,271. Cancer Research, 68(6), 1935–1944. https://doi.org/10.1158/0008-5472.Can-07-5155
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. (2013). Ptraj and Cpptraj: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084–3095. https://doi.org/10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. (2018). Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data. Journal of Computational Chemistry, 39(25), 2110–2117. https://doi.org/10.1002/jcc.25382
   PubMed Web of Science ®Google Scholar
• Roskoski, R. (2016). Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Research, 103, 26–48. https://doi.org/10.1016/j.phrs.2015.10.021
   PubMed Web of Science ®Google Scholar
• Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977). Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of N-alkanes. Journal of Computational Physics. 23(3), 327–341. https://doi.org/10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Saha, B. C., Kumari, R., Kushumesh, R., Ambasta, A., & Sinha, B. P. (2021). Status of rho kinase inhibitors in glaucoma therapeutics—an overview. International Ophthalmology, 42(1), 281-294. https://doi.org/10.1007/s10792-021-02002-w
   Google Scholar
• Salmaso, V., & Jacobson, K. A. (2020). In silico drug design for purinergic gpcrs: overview on molecular dynamics applied to adenosine and P2y receptors. Biomolecules, 10(6), 812. https://doi.org/10.3390/biom10060
   PubMed Web of Science ®Google Scholar
• Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., Lescrinier, E., Marimuthu, P., Mirza, M. U., Mustafa, G., Nunes-Alves, A., Pantsar, T., Saadabadi, A., Singaravelu, K., & Vanmeert, M. (2020). Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes, 9(1), 71. https://doi.org/10.3390/pr9010071
   Web of Science ®Google Scholar
• Sanner, M. F. (1999). Python: A programming language for software integration and development. The Journal of Molecular Graphics, 17(1), 57–61.
   Google Scholar
• Sanner, M. F., Dieguez, L., Forli, S., & Lis, E. (2021). Improving docking power for short peptides using random forest. Journal of Chemical Information and Modeling, 61(6), 3074–3090. https://doi.org/10.1021/acs.jcim.1c00573
   PubMed Web of Science ®Google Scholar
• Sen Gupta, P. S., Biswal, S., Panda, S. K., Ray, A. K., & Rana, M. K. (2022). Binding mechanism and structural insights into the identified protein target of Covid-19 and importin-Alpha with in-vitro effective drug ivermectin. Journal of Biomolecular Structure & Dynamics, 40(5), 2217–2226. https://doi.org/10.1080/07391102.2020.1839564
   PubMed Web of Science ®Google Scholar
• Shah, N. R., Tancioni, I., Ward, K. K., Lawson, C., Chen, X. L., Jean, C., Sulzmaier, F. J., Uryu, S., Miller, N. L., Connolly, D. C., & Schlaepfer, D. D. (2014). Analyses of merlin/Nf2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecologic Oncology, 134(1), 104–111. https://doi.org/10.1016/j.ygyno.2014.04.044
   PubMed Web of Science ®Google Scholar
• Shanthi, E., Krishna, M. H., Arunesh, G. M., Reddy, K. V., Kumar, J. S., & Viswanadhan, V. N. (2014). Focal adhesion kinase inhibitors in the treatment of metastatic cancer: A patent review. Expert Opinion on Therapeutic Patents, 24(10), 24. https://doi.org/10.1517/13543776.2014.948845
   Web of Science ®Google Scholar
• Shapiro, I. M., Kolev, V. N., Vidal, C. M., Kadariya, Y., Ring, J. E., Wright, Q., Weaver, D. T., Menges, C., Padval, M., McClatchey, A. I., Xu, Q., Testa, J. R., & Pachter, J. A. (2014). Merlin deficiency predicts Fak inhibitor sensitivity: A synthetic lethal relationship. Science Translational Medicine, 6(237), 11. https://doi.org/10.1126/scitranslmed.3008639
   Web of Science ®Google Scholar
• Shen, T., & Guo, Q. (2020). EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2. Cell Biology International, 44(1), 2–13. https://doi.org/10.1002/cbin.11209
   PubMed Web of Science ®Google Scholar
• Shi, M., Chen, T., Wei, S., Zhao, C., Zhang, X., Li, X., Tang, X., Liu, Y., Yang, Z., & Chen, L. (2022). Molecular docking, molecular dynamics simulations, and free energy calculation insights into the binding mechanism between vs-4718 and focal adhesion kinase. ACS Omega, 7(36), 32442–32456. https://doi.org/10.1021/acsomega.2c03951
   PubMedGoogle Scholar
• Shi, M., Wang, L., Li, P., Liu, J., Chen, L., & Xu, D. (2021). Dasatinib-Sik2 binding elucidated by homology modeling, molecular docking, and dynamics simulations. ACS Omega, 6(16), 11025–11038. https://doi.org/10.1021/acsomega.1c00947
   PubMed Web of Science ®Google Scholar
• Shi, M., Wang, L., Liu, K., Chen, Y., Hu, M., Yang, L., He, J., Chen, L., & Xu, D. (2022). Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (Sik2) multi-state binding with bosutinib. Computational and Structural Biotechnology Journal, 20, 2574–2586. https://doi.org/10.1016/j.csbj.2022.05.039
   PubMed Web of Science ®Google Scholar
• Shi, M., Zhao, M., Wang, L., Liu, K., Li, P., Liu, J., Cai, X., Chen, L., & Xu, D. (2021). Exploring the stability of inhibitor binding to Sik2 using molecular dynamics simulation and binding free energy calculation. Physical Chemistry Chemical Physics, 23(23), 13216–13227. https://doi.org/10.1039/d1cp00717c
   PubMed Web of Science ®Google Scholar
• Shimizu, T., Fukuoka, K., Takeda, M., Iwasa, T., Yoshida, T., Horobin, J., Keegan, M., Vaickus, L., Chavan, A., Padval, M., & Nakagawa, K. (2016). A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of Vs-6063, a Focal adhesion kinase (Fak) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 77(5), 997–1003. https://doi.org/10.1007/s00280-016-3010-1
   PubMed Web of Science ®Google Scholar
• Shinada, N. K., de Brevern, A. G., & Schmidtke, P. (2019). Halogens in protein-ligand binding mechanism: A structural perspective. Journal of Medicinal Chemistry, 62(21), 9341–9356. https://doi.org/10.1021/acs.jmedchem.8b01453
   PubMed Web of Science ®Google Scholar
• Shirvani, P., & Fassihi, A. (2022). In silico design of novel Fak inhibitors using integrated molecular docking, 3d-Qsar and molecular dynamics simulation studies. Journal of Biomolecular Structure & Dynamics, 40(13), 5965–5982. https://doi.org/10.1080/07391102.2021.1875880
   PubMed Web of Science ®Google Scholar
• Sivakumar, K. C., Jin, H. X., Naman, C. B., & Sajeevan, T. P. (2020). Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process. Drug Development Research, 81(6), 685–699. https://doi.org/10.1002/ddr.21673
   PubMed Web of Science ®Google Scholar
• Song, X., Xu, H., Wang, P., Wang, J., Affo, S., Wang, H., Xu, M., Liang, B., Che, L., Qiu, W., Schwabe, R. F., Chang, T. T., Vogl, M., Pes, G. M., Ribback, S., Evert, M., Chen, X., & Calvisi, D. F. (2021). Focal adhesion kinase (Fak) promotes cholangiocarcinoma development and progression via Yap activation. Journal of Hepatology, 75(4), 888–899. https://doi.org/10.1016/j.jhep.2021.05.018
   PubMed Web of Science ®Google Scholar
• Soria, J. C., Gan, H. K., Blagden, S. P., Plummer, R., Arkenau, H. T., Ranson, M., Evans, T. R. J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., … Millward, M. (2016). A Phase I, pharmacokinetic and pharmacodynamic study of Gsk2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 27(12), 2268–2274. https://doi.org/10.1093/annonc/mdw427
   PubMed Web of Science ®Google Scholar
• Srinivasan, J., Cheatham, T. E., Cieplak, P., Kollman, P. A., & Case, D. A. (1998). Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate—DNA helices. Journal of the American Chemical Society, 120(37), 9401–9409. https://doi.org/10.1021/ja981844+
   Web of Science ®Google Scholar
• Srinivasan, J., Trevathan, M. W., Beroza, P., & Case, D. A. (1999). Application of a pairwise generalized born model to proteins and nucleic acids: Inclusion of salt effects. Theoretical Chemistry Accounts, 101(6), 426–434. https://doi.org/10.1007/s002140050460
   Web of Science ®Google Scholar
• Stewart, J. J. P. (1989). Optimization of parameters for semi-empirical methods I-method. Journal of Computational Chemistry, 10(2), 209–220. https://doi.org/10.1002/jcc.540100208
   Web of Science ®Google Scholar
• Still, W. C., Tempczyk, A., Hawley, R. C., & Hendrickson, T. (1990). Semianalytical treatment of solvation for molecular mechanics and dynamics. Journal of the American Chemical Society, 112(16), 6127–6129. https://doi.org/10.1021/ja00172a038
   Web of Science ®Google Scholar
• Su, M. Y., Yang, Q. F., Du, Y., Feng, G. Q., Liu, Z. H., Li, Y., & Wang, R. X. (2019). Comparative assessment of scoring functions: The casf-2016 update. Journal of Chemical Information and Modeling, 59(2), 895–913. https://doi.org/10.1021/acs.jcim.8b00545
   PubMed Web of Science ®Google Scholar
• Sun, C. C., Feng, L. J., Sun, X. H., Yu, R. L., & Kang, C. M. (2021). Design and screening of Fak, Cdk 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation. Journal of Biomolecular Structure & Dynamics, 39(15), 5358–5367. https://doi.org/10.1080/07391102.2020.1786458
   PubMed Web of Science ®Google Scholar
• Sun, Z. C., Jiang, Q. W., Li, J., & Guo, J. P. (2020). The potent roles of salt-inducible kinases (Siks) in metabolic homeostasis and tumorigenesis. Signal Transduction and Targeted Therapy, 5(1), 150. https://doi.org/10.1038/s41392-020-00265-w
   PubMed Web of Science ®Google Scholar
• Tanjoni, I., Walsh, C., Uryu, S., Tomar, A., Nam, J.-O., Mielgo, A., Lim, S.-T., Liang, C., Koenig, M., Sun, C., Patel, N., Kwok, C., McMahon, G., Stupack, D. G., & Schlaepfer, D. D. (2010). Pnd-1186 Fak inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biology & Therapy, 9(10), 764–777. https://doi.org/10.4161/cbt.9.10.11434
   PubMed Web of Science ®Google Scholar
• The PYMOL Molecular Graphics System, Version 2.0, Schrödinger, LLC.
   Google Scholar
• Thifault, D. G., Fromme, P., & Martin-Garcia, J. M. (2020). Hydrocarbon-stapled paxillin peptide bound to the focal adhesion targeting (fat) domain of the focal adhesion kinase (Fak). https://doi.org/10.2210/pdb6PW8/pdb
   Google Scholar
• Tian, C., Kasavajhala, K., Belfon, K. A. A., Raguette, L., Huang, H., Migues, A. N., Bickel, J., Wang, Y., Pincay, J., Wu, Q., & Simmerling, C. (2020). Ff19sb: Amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. Journal of Chemical Theory and Computation, 16(1), 528–552. https://doi.org/10.1021/acs.jctc.9b00591
   PubMed Web of Science ®Google Scholar
• Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., Xie, D., Zhang, Y., & Klei, H. E. (2006). The structure of dasatinib (Bms-354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants. Cancer Research, 66(11), 5790–5797. https://doi.org/10.1158/0008-5472.Can-05-4187
   PubMed Web of Science ®Google Scholar
• Tomita, N., Hayashi, Y., Suzuki, S., Oomori, Y., Aramaki, Y., Matsushita, Y., Iwatani, M., Iwata, H., Okabe, A., Awazu, Y., Isono, O., Skene, R. J., Hosfield, D. J., Miki, H., Kawamoto, T., Hori, A., & Baba, A. (2013). Structure-based discovery of cellular-active allosteric inhibitors of Fak. Bioorganic & Medicinal Chemistry Letters, 23(6), 1779–1785. https://doi.org/10.1016/j.bmcl.2013.01.047
   PubMed Web of Science ®Google Scholar
• Vilar, S., & Costanzi., S. (2013). Application of Monte Carlo-based receptor ensemble docking to virtual screening for GPCR ligands. In Conn, P. M. (Ed.), G Protein Coupled Receptors: Modeling, Activation, Interactions and Virtual Screening, Methods in Enzymology (Vol. 522, 263–278). Elsevier Academic Press Inc.
   Google Scholar
• Wang, J. M., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Wang, L., Zheng, Y., Li, D., Yang, J., Lei, L., Yan, W., Zheng, W., Tang, M., Shi, M., Zhang, R., Cai, X., Ni, H., Ma, X., Li, N., Hong, F., Ye, H., & Chen, L. (2021). Design, synthesis, and bioactivity evaluation of dual-target inhibitors of tubulin and Src kinase guided by crystal structure. Journal of Medicinal Chemistry, 64(12), 8127–8141. https://doi.org/10.1021/acs.jmedchem.0c01961
   PubMed Web of Science ®Google Scholar
• Waseem, R., Shamsi, A., Khan, T., Hassan, M. I., Kazim, S. N., Shahid, M., & Islam, A. (2022). Unraveling the binding mechanism of Alzheimer’s Drugs with irisin: Spectroscopic, calorimetric, and computational approaches. International Journal of Molecular Sciences, 23(11), 5965. https://doi.org/10.3390/ijms23115965
   PubMed Web of Science ®Google Scholar
• Weiser, J., Shenkin, P. S., & Still, W. C. (1999). Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). Journal of Computational Chemistry, 20(2), 217–230. https://doi.org/10.1002/(sici)1096-987x(19990130)20:2 < 217::Aid-jcc4 > 3.0.Co;2-a
   Web of Science ®Google Scholar
• Wu, C. H., Apweiler, R., Bairoch, A., Natale, D. A., Barker, W. C., Boeckmann, B., Ferro, S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M., Martin, M. J., Mazumder, R., O'Donovan, C., Redaschi, N., & Suzek, B. (2006). The universal protein resource (Uniprot): An expanding universe of protein information. Nucleic Acids Research, 34(Database issue), D187–D191. https://doi.org/10.1093/nar/gkj161
   PubMed Web of Science ®Google Scholar
• Wu, Y. L., Li, N., Ye, C. F., Jiang, X. M., Luo, H., Zhang, B. Y., Zhang, Y., & Zhang, Q. Y. (2021). Focal adhesion kinase inhibitors, a heavy punch to cancer. Discover Oncology, 12(1), 15. https://doi.org/10.1007/s12672-021-00449-y
   PubMedGoogle Scholar
• Xia, H., Nho, R. S., Kahm, J., Kleidon, J., & Henke, C. A. (2004). Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a Beta(1) integrin viability signaling pathway. The Journal of Biological Chemistry, 279(31), 33024–33034. https://doi.org/10.1074/jbc.M313265200
   PubMed Web of Science ®Google Scholar
• Xu, Z., Liu, Z., Chen, T., Chen, T., Wang, Z., Tian, G., Shi, J., Wang, X., Lu, Y., Yan, X., Wang, G., Jiang, H., Chen, K., Wang, S., Xu, Y., Shen, J., & Zhu, W. (2011). Utilization of halogen bond in lead optimization: A case study of rational design of potent phosphodiesterase type 5 (Pde5) inhibitors. Journal of Medicinal Chemistry, 54(15), 5607–5611. https://doi.org/10.1021/jm200644r
   PubMed Web of Science ®Google Scholar
• Yang, J. Y., Lin, X. Y., Xing, N., Zhang, Z., Zhang, H. W., Wu, H. B., & Xue, W. W. (2021). Structure-based discovery of novel nonpeptide inhibitors targeting Sars-Cov-2 M-Pro. Journal of Chemical Information and Modeling, 61(8), 3917–3926. https://doi.org/10.1021/acs.jcim.1c00355
   PubMed Web of Science ®Google Scholar
• Yang, T., Cui, X., Tang, M., Qi, W., Zhu, Z., Shi, M., Yang, L., Pei, H., Zhang, W., Xie, L., Xu, Y., Yang, Z., & Chen, L. (2022). Identification of a novel 2,8-diazaspiro 4.5 decan-1-one derivative as a potent and selective dual tyk2/jak1 inhibitor for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry, 65(4), 3151–3172. https://doi.org/10.1021/acs.jmedchem.1c01137
   PubMed Web of Science ®Google Scholar
• Yang, T., Hu, M., Chen, Y., Xiang, M., Tang, M., Qi, W., Shi, M., He, J., Yuan, X., Zhang, C., Liu, K., Li, J., Yang, Z., & Chen, L. (2020). N-(pyrimidin-2-Yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective janus kinase 2 inhibitors for the treatment of myeloproliferative neoplasms. Journal of Medicinal Chemistry, 63(23), 14921–14936. https://doi.org/10.1021/acs.jmedchem.0c01488
   PubMed Web of Science ®Google Scholar
• Yen-Pon, E., Li, B., Acebrón-Garcia-de-Eulate, M., Tomkiewicz-Raulet, C., Dawson, J., Lietha, D., Frame, M. C., Coumoul, X., Garbay, C., Etheve-Quelquejeu, M., & Chen, H. (2018). Structure-based design, synthesis, and characterization of the first irreversible inhibitor of focal adhesion kinase. ACS Chemical Biology, 13(8), 2067–2073. https://doi.org/10.1021/acschembio.8b00250
   PubMed Web of Science ®Google Scholar
• Yuce, M., Sarica, Z., Ates, B., & Kurkcuoglu, O. (2022). Exploring species-specific inhibitors with multiple target sites on S. Aureus pyruvate kinase using a computational workflow. Journal of Biomolecular Structure and Dynamics, https://doi.org/10.1080/07391102.2022.2051743
   Google Scholar
• Zhan, J. Y., Zhang, J. L., Wang, Y., Li, Y., Zhang, H. X., & Zheng, Q. C. (2016). Exploring the interaction between human focal adhesion kinase and inhibitors: A molecular dynamic simulation and free energy calculations. Journal of Biomolecular Structure & Dynamics, 34(11), 2351–2366. https://doi.org/10.1080/07391102.2015.1115780
   PubMed Web of Science ®Google Scholar
• Zhang, Y. M., Liu, S., Zhou, S., Yu, D. D., Gu, J. J., Qin, Q., Cheng, Y., & Sun, X. C. (2021). Focal adhesion kinase: insight into its roles and therapeutic potential in oesophageal cancer. Cancer Letters, 496, 93–103. https://doi.org/10.1016/j.canlet.2020.10.005
   PubMed Web of Science ®Google Scholar
• Zhou, J., Bronowska, A., Le Coq, J., Lietha, D., & Grater, F. (2015). Allosteric regulation of focal adhesion kinase by PIP2 and ATP. Biophysical Journal, 108(3), 698–705. https://doi.org/10.1016/j.bpj.2014.11.3454
   PubMed Web of Science ®Google Scholar